Highlights

  • Atlas Arteria has lodged a Second Supplementary Target’s Statement in response to IFM’s Takeover bid.
  • Independent Directors continue to unanimously recommend that securityholders reject the offer.
  • The company responded to IFM’s Fourth Supplementary Bidder’s Statement released on 3 June 2026.
  • Atlas Arteria noted that the offer remains subject to multiple conditions and that no conditions have been waived or satisfied.
  • The company highlighted that the Offer Period has been extended to 18 June 2026 and stated that shareholders face no urgency in making a decision.

Atlas Arteria Group (ASX:ALX) shares were trading marginally higher at AUD 5.08 during the morning session on 5 June 2026 after the company released a further response to the ongoing takeover proposal from IFM Global Infrastructure Fund. The latest announcement outlined Atlas Arteria’s Second Supplementary Target’s Statement and reiterated the board’s recommendation that securityholders reject the current offer.

Although the stock edged up 0.099% during the session, Atlas Arteria shares remain down approximately 4.43% over the past year. The latest update does not involve changes to the company's operating performance or financial outlook but instead forms part of the continuing engagement between Atlas Arteria and IFM regarding the proposed Acquisition of the company.

Atlas Arteria is a global toll road operator with interests across Europe and North America. The group's portfolio includes motorway Assets in France, toll road operations in the United States and the Warnow Tunnel in Germany. Through these infrastructure assets, the company generates Revenue from long-term transportation networks serving millions of users annually.

Company Issues Further Response to IFM Bid

The latest announcement follows a series of documents exchanged between Atlas Arteria and IFM as part of the takeover process.

Atlas Arteria confirmed that it had lodged its Second Supplementary Target’s Statement with both the Australian Securities and Investments Commission (ASIC) and the Australian Securities Exchange (ASX). The document supplements the Target’s Statement released on 26 May 2026 and the First Supplementary Target’s Statement issued on 2 June 2026.

According to the company, the latest supplementary document provides additional information in response to IFM’s Fourth Supplementary Bidder’s Statement, which was released on 3 June 2026.

Importantly, Atlas Arteria stated that the Independent Directors continue to unanimously recommend that securityholders reject the offer.

The company advised investors that shareholders who wish to reject the proposal do not need to take any action and can simply disregard documents sent by the bidder.

Takeover Process Continues to Evolve

The ongoing proposal relates to an off-market takeover offer made by Diamond Infraco 1 Pty Ltd, a Wholly Owned Subsidiary of IFM Global Infrastructure Fund.

The bidder is seeking to acquire all fully paid stapled securities in Atlas Arteria that it does not already own.

While the takeover process has progressed through several rounds of bidder and target statements, Atlas Arteria's latest release indicates that its position remains unchanged.

Management's focus in the supplementary statement was to address developments contained in the bidder's most recent disclosure and provide additional information for shareholders evaluating the proposal.

The company stressed that its latest supplementary statement should be read alongside previous communications released during the offer process.

Offer Period Extended by One Week

One of the key developments highlighted in the announcement relates to the extension of the offer period.

Atlas Arteria noted that IFM has extended the offer period by one week, with the proposal now scheduled to close at 7:00pm Sydney time on 18 June 2026 unless further extended or withdrawn.

The company pointed out that the bidder did not make any other changes to the offer when announcing the extension.

According to Atlas Arteria, the offer continues to be subject to a number of conditions. The company stated that the bidder has not waived any of those conditions nor announced the satisfaction of any conditions as part of its latest supplementary bidder statement.

As a result, Atlas Arteria emphasised that the offer remains highly conditional.

Atlas Arteria Questions Timing of Extension

The supplementary statement also addressed the timing of the bidder's decision to extend the offer period.

Atlas Arteria noted that the extension occurred one day before the bidder would otherwise have been required to provide a Notice of Status of Conditions.

That notice would typically require disclosure of the bidder's voting power in Atlas Arteria.

The company suggested that extending the offer period delayed the requirement for such disclosure.

Atlas Arteria further stated that no announcement had been made indicating any increase of at least one percentage point in the bidder's voting power, a threshold that would require disclosure to the market.

Based on publicly available information at the time of the announcement, the company indicated that acceptances of the offer appeared limited.

Board Maintains Unanimous Recommendation

A central message throughout the supplementary statement is the continued opposition of Atlas Arteria's Independent Directors to the offer.

The board reiterated its recommendation that securityholders reject the proposal at both the original Offer Price of AUD 4.75 and the revised offer price of AUD 5.10.

Management's latest communication is designed to reinforce that recommendation while providing shareholders with additional context surrounding the bid process.

The company also reminded investors that they will have sufficient time to assess developments before making any decision if circumstances change during the offer period.

According to Atlas Arteria, there is currently no urgency for shareholders to accept the proposal.

Company Highlights Potential Future Value Considerations

Another point raised in the supplementary statement relates to future acquisition possibilities following the end of the offer period.

Atlas Arteria noted that while the bidder had committed to adjusting the offer price for distributions declared during the offer period, it had not made a similar commitment regarding acquisitions after the offer period concludes.

The company suggested that this leaves open the possibility that shareholders could potentially receive consideration that includes both acquisition value and distributions under certain future scenarios.

Atlas Arteria also reaffirmed its previously announced ordinary distribution guidance of 40.0 cents per security for 2026.

Additionally, the company noted that proceeds from any future asset sales could potentially be available for return to securityholders, although it highlighted that distribution guidance remains subject to Business performance, taxation changes, foreign exchange movements and other future events.

Atlas Arteria’s Infrastructure Portfolio

While the announcement primarily focused on the takeover process, Atlas Arteria also highlighted the nature of its existing infrastructure portfolio.

The group owns a 30.8% interest in a 2,424-kilometre motorway network in eastern France, including APRR, AREA, A79 and ADELAC.

In the United States, Atlas Arteria holds a 66.67% interest in the Chicago Skyway, a 12.5-kilometre toll road located in Chicago.

The company also owns the economic interest in the 22-kilometre Dulles Greenway toll road in Virginia.

In Germany, Atlas Arteria owns the Warnow Tunnel in Rostock.

These transportation infrastructure assets form the foundation of the company's long-term business model and are central to the value proposition currently being assessed by shareholders during the takeover process.

Shareholders Encouraged to Review Available Information

Atlas Arteria encouraged investors to review all available materials relating to the offer before making a decision.

The company specifically referenced its original Target’s Statement, the Independent Expert’s Report and the supplementary statements issued during the process.

Management also encouraged shareholders to seek independent financial, legal, taxation or other professional advice where appropriate based on their individual circumstances.

The latest supplementary statement was approved by the company's Independent Directors and formally lodged with regulators on 5 June 2026.

What This Means for Investors

Atlas Arteria's latest announcement does not introduce a new offer or alter the existing proposal but instead reinforces the company's position in response to recent developments from the bidder.

The key message remains that the Independent Directors continue to unanimously recommend rejecting the IFM-backed offer. The company has also highlighted that the bid remains conditional and that shareholders have time available to assess future developments before any final decision may be required.

Investors following the takeover process will likely continue monitoring further disclosures from both Atlas Arteria and IFM, particularly as the revised offer deadline of 18 June 2026 approaches.